Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
  • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Definitions

• the present invention is related to fat milk containing a profile scan data Grad Nji down I 2 class.
• te Grad down di emissions I 2 such as the therapeutic agents for diseases of the circulatory system to troduction antithrombotic agents Related to fat emulsion.
• Prostaglandins exhibit a wide variety of physiological activities, and are used as drugs and pharmaceuticals by various useful physiological actions such as peripheral circulation improvement, vasodilation, anti-ulcer, hypotension, pregnancy control, antithrombosis, and anti-asthma. It is being used. Recently, applications to new fields such as anticancer, bone metabolism improvement, antivirus, liver protection, and diuresis are also being studied.
• natural prostacyclin is a hormone that is mainly produced in the living body mainly on the inner wall of arterial blood vessels, and has a strong physiological activity, such as a platelet aggregation inhibitory activity. It is an important factor that regulates cellular functions of living organisms by vasodilatory activity, etc., and attempts have been made to provide this directly as a drug [P. J. Lewis, J. et al.
• X represents an oxygen atom or a methine group
• Y represents a carbon atom
• Z represents a methylene group or a methine group
• the bonding mode of Y-Z is a carbon-carbon double bond
• X is a methine group
• the bonding mode of X-Y is a carbon-carbon double bond
• Z is a carbon-carbon double bond. It is a styrene group.
• R 1 is a hydrogen atom or an alkyl group
• R 2 is a hydrogen atom or a fluorine atom
• R 3 is a hydrogen atom, a methyl group, an ethyl group, or a vinyl group.
• R 4 is a substituted or unsubstituted alkyl group having 1 to 10 carbon atoms, a substituted or unsubstituted alkenyl group having 2 to 10 carbon atoms,
• This is a fat emulsion containing a prostaglandin I 2 represented by '.
• the fat emulsion of the present invention is a novel fat emulsion containing chemically stable prostaglandin I 2, and such a fat emulsion has a long-lasting action. Gras emissions di down 1 2 such Ri Contact lowered improved stability and side effects, or pharmacological action of Taso also strongly useful as a intravenous formulation.
• X represents an oxygen atom or a methine group
• Y represents a carbon atom
• Z represents a methylene group or a methine group.
• the bond mode of Z is a carbon-carbon double bond
• X is a methine group
• the bond mode of XY is a carbon-carbon double bond
• Z is a methylene group.
• R 1 , R 3 , R 4 , and n are as defined above.
• ⁇ Represents a hydrogen atom.
• R 1 , R 3 , R and n are as defined above.
• R 2 represents a hydrogen atom.
• R 1 represents a hydrogen atom or an alkyl group.
• alkyl group examples include an alkyl group having 1 to 10 carbon atoms such as methyl, ethyl, propyl, butyl, pentyl, hexyl, butyl, decyl, and the like.
• R 1 is preferably a hydrogen atom or a methyl group.
• R 4 is a substituted or unsubstituted alkyl having 1 to 10 carbon atoms, an substituted or unsubstituted alkenyl group having 2 to 10 carbon atoms, or a substituted or unsubstituted alkenyl group having 2 to 10 carbon atoms. It represents an unsubstituted alkynyl group or a substituted or unsubstituted cycloal group having 3 to 8 carbon atoms. Examples of the unsubstituted alkyl group having 1 to 10 carbon atoms include methyl, ethyl, propyl, butyl, pentyl, hexyl, octyl, decyl, and the like.
• Examples of the unsubstituted alkenyl group having 2 to 10 carbon atoms include vinyl 2-propenyl, 3-butenyl, 2-pentenyl, 2-methyl-3-pentenyl, and 2-— Xenyl, 5-methyl-14-hexenyl, 2,6-dimethyl-5-heptenyl and the like can be mentioned.
• Examples of the unsubstituted alkynyl group having 2 to 10 carbon atoms include 2-butynyl, 3-butynyl, 1-methyl-12-pentynyl, 1-methyl-3-pentynyl, and 2-pentynyl. And 4-hexynyl group.
• Carbon number Examples of the 3 to 8 unsubstituted cycloalkyl groups include cyclopropyl, cyclopentyl, cyclohexyl and the like.
• Substituents of these alkyl, alkenyl, alkynyl and cycloalkyl groups include halogen atoms such as fluorine, chlorine, etc .; methoxy, ethoxy, and propyl. Lower alkoxy groups such as poxoxy and propyloxy groups; halogenated alkyl groups such as trifluoromethyl group; halogen atoms substituted with lower alkoxy groups. Or an unsubstituted amino group.
• the fat emulsion of the present invention comprises a prostaglandin of the formula [I].
• Class I2 5-50 WZ V% vegetable oil, 1-50 parts per 100 parts vegetable oil, preferably 5-30 parts of phospholipids and mainly water
• Vegetable oils include soybean oil, cottonseed oil, sesame oil, safflower oil, corn oil, and the like, with soybean oil being preferred.
• the soybean oil is preferably high-purity refined soybean oil, preferably refined soybean oil, for example, by steam distillation. This is a purified soybean oil of high purity.
• the phospholipid is a purified phospholipid such as egg yolk lecithin and soybean lecithin, and can be used after being prepared by a conventional method of fractionation using an organic solvent. That is, for example, crude egg yolk phospholipids are dissolved in cold n-hexane-aceton, and acetone is gradually added under stirring, and the insoluble matter is separately collected. After repeating the above operation once more, the purified phospholipid obtained by distilling off the solvent can be used. It is mainly composed of phosphatidylcholine and phosphatidylethanolamine. Other phospholipids include phosphatidylinositol, phosphatidylserine, sphingomyelin, and the like.
• an emulsifying aid if necessary, an emulsifying aid, a stabilizer, a polymer substance, a tonicity agent and the like can be further added.
• fatty acids of 6 to 22 carbon atoms for example, fatty acids of 6 to 22 carbon atoms, preferably up to 0.3 w / V%, preferably 12 to 20 or their pharmaceutically acceptable
• salts Any of these fatty acids having 6 to 22 carbon atoms can be used as long as they can be added to pharmaceuticals.
• Such fatty acids may be straight-chain or branched, and include stearic acid, perylene acid, linoleic acid, palmitic acid, linolenic acid, and myristic acid. Which is preferred.
• These salts include, for example, alkali metal salts such as sodium salts and potassium salts, and alkaline earth salts such as calcium salts. The use of metal etc. can be achieved.
• cholesterols for example, cholesterols of 0.5 w / v 96 or less, preferably 0.1 w / V% or less, or 5 wZv% or less, preferably 1 wZv% or less Amount of phosphatidic acid, etc.
• examples include vinyl polymers, nonionic surfactants, gelatin, and hydroxyxetil powder.
• albumin a human-derived one is preferred, and as the vinyl polymer, polyvinylpyrrolidone and the like can be mentioned.
• nonionic surfactants include polyalkylene glycol, polyalkylene alkylene copolymer, hydrogenated castor oil polyalkylene derivative, and castor oil. It can be cited as oil polyalkylene derivatives.
• the content of fat in the emulsion of the profile is te Gras Nji down I 2 include, but may be appropriately increased blinking in Tsu by the emulsion of the form you and use, generally if example door was a very small amount in the fat emulsion 1.0fl ⁇ It is enough to contain up to 0.2 sP / ffl2.
• the fat emulsion of the present invention is produced, for example, by the following method. That is, a predetermined amount of vegetable oil, phospholipid, prostaglandin 12 and other additives are mixed and ripened. The solution is homogenized using a conventional homogenizer, for example, a pressurized injection homogenizer, an ultrasonic homogenizer, etc., and then a required amount of water is added. Then, the homogenizer is again homogenized to produce the fat emulsion of the present invention. Depending on the production convenience, additives such as a stabilizer and an isotonic agent may be added after the formation of the fat emulsion.
• a stabilizer and an isotonic agent may be added after the formation of the fat emulsion.
• the fat emulsion of the present invention can be administered parenterally such as injection, and intravenous administration is particularly preferred. If for example, the administration profile is te Gras Nji down 1 class 2 and to 0.01 ⁇ 0.1 gt / / is!
• the lipid emulsion of the present invention has a strong action, has a sustained-release property, and has lesion selectivity, so that it can be effectively treated by a small amount of administration.
• the particles are extremely fine, the average particle size is 1.0 or less, and the storage stability is extremely good.
• the time-dependent changes in the production of the cyclic emulsion AMP (Cyclic AMP) of the fat emulsion of the present invention were measured using human platelets, and compared with those of the non-fat emulsion compound.
• Human blood 50 ⁇ was collected at a ratio of 9 volumes of blood to 1 volume of 3.8% sodium citrate, and centrifuged at 1300 rpm for 10 minutes. Separate the upper layer as PRP (platelet-rich blood) and centrifuge at 3000 rpm for 20 minutes.
• the precipitate (platelets) obtained is a tris buffer solution, saline, glucose—EDTA (PH 7.4). 2 Put the TSG — EDTA 350 ⁇ Q.
• Physiological saline 10 14.1 41.1 The power sale by kana Table 2 or Akira Luo et al, the Te fat emulsion odor of the present invention, pro static Gras Nji down 1 2 such that the active ingredient is released gradually, with a sustained release.
• Fat milk containing a pro scan data Grad Nji down 1 2 compounds of the present invention its effect will have a sustained release powerful, because lesions selectivity there Ru, effective in Tsu by the small amount of administration It can be treated and is extremely useful as a therapeutic agent for cardiovascular diseases including antithrombotic agents.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Molecular Biology (AREA)
• Dispersion Chemistry (AREA)
• Biophysics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Medicinal Preparation (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=15021666

Family Applications (1)

Country Status (9)

Cited By (2)

Families Citing this family (12)

Citations (9)

Family Cites Families (11)

• 1985
  • 1985-06-17 JP JP60129920A patent/JPS61289034A/ja active Granted
• 1986
  • 1986-06-12 WO PCT/JP1986/000293 patent/WO1986007538A1/ja not_active Ceased
  • 1986-06-12 AU AU59631/86A patent/AU591138B2/en not_active Ceased
  • 1986-06-12 AT AT86903594T patent/ATE74506T1/de not_active IP Right Cessation
  • 1986-06-12 EP EP86903594A patent/EP0229844B1/en not_active Expired - Lifetime
  • 1986-06-12 DE DE8686903594T patent/DE3684771D1/de not_active Expired - Lifetime
• 1987
  • 1987-02-17 DK DK080487A patent/DK169056B1/da not_active IP Right Cessation
  • 1987-02-17 FI FI870663A patent/FI88583C/fi not_active IP Right Cessation
• 1991
  • 1991-07-05 US US07/727,376 patent/US5124352A/en not_active Expired - Fee Related

Patent Citations (9)

Also Published As

Similar Documents

Legal Events